.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Healthtrust
Deloitte
US Army
Argus Health
Cipla
Cerilliant
Johnson and Johnson
Fuji
Covington

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,619,001

« Back to Dashboard

Which drugs does patent 7,619,001 protect, and when does it expire?


Patent 7,619,001 protects TECFIDERA and is included in one NDA. There has been one Paragraph IV challenge on Tecfidera.

This patent has forty-five patent family members in thirty countries.

Summary for Patent: 7,619,001

Title:Utilization of dialkylfumarates
Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Inventor(s): Joshi; Rajendra Kumar (Zurich, CH), Strebel; Hans-Peter (Muri, CH)
Assignee: Biogen IDEC International GmbH (Zug, CH)
Application Number:11/765,578
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Biogen Idec Inc
TECFIDERA
dimethyl fumarate
CAPSULE, DELAYED RELEASE;ORAL204063-001Mar 27, 2013RXYesNo► Subscribe► Subscribe METHOD OF TREATING MULTIPLE SCLEROSIS
Biogen Idec Inc
TECFIDERA
dimethyl fumarate
CAPSULE, DELAYED RELEASE;ORAL204063-002Mar 27, 2013RXYesYes► Subscribe► Subscribe METHOD OF TREATING MULTIPLE SCLEROSIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,619,001

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany198 53 487Nov 19, 1998

Non-Orange Book Patents for Patent: 7,619,001

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,759,393Utilization of dialkylfumarates► Subscribe
6,509,376 Utilization of dialkyfumarates► Subscribe
7,803,840Utilization of dialkylfumarates► Subscribe
8,524,773Utilization of dialkylfumarates► Subscribe
7,612,110Utilization of dialkylfumarates► Subscribe
7,320,999Dimethyl fumarate for the treatment of multiple sclerosis► Subscribe
7,915,310Utilization of dialkylfumarates► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,619,001

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland226074► Subscribe
Norway20121479► Subscribe
Slovenia1131065► Subscribe
Norway333257► Subscribe
Russian Federation2215524► Subscribe
Serbia49995► Subscribe
Yugoslavia29901► Subscribe
Portugal1131065► Subscribe
New Zealand510247► Subscribe
Poland348147► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Teva
Chinese Patent Office
McKinsey
Fuji
Covington
Chubb
Queensland Health
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot